---
title: "What's Going On With Polaryx Therapeutics Stock Wednesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276246669.md"
description: "Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell 22.47% to $3.07 on Wednesday, reversing gains from a 64.32% surge the previous day following a major clinical development announcement. The company selected a contract research organization for its SOTERIA Phase 2 trial, evaluating its lead candidate PLX-200 for lysosomal storage disorders, with the trial set to begin in 2026. Despite the recent spike, PLYX has declined 88.69% over the past year, remaining closer to its 52-week low of $2.20 than its high of $48.91."
datetime: "2026-02-18T15:19:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276246669.md)
  - [en](https://longbridge.com/en/news/276246669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276246669.md)
---

# What's Going On With Polaryx Therapeutics Stock Wednesday?

**Polaryx Therapeutics Inc.** (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.

The stock closed Tuesday up 64.32% at $3.96, after the company announced it had selected a contract research organization (CRO) for its SOTERIA Phase 2 basket trial.

The trial is designed to evaluate PLX-200, Polaryx’s lead candidate, across multiple lysosomal storage disorders.

Polaryx said the CRO selection marks a pivotal milestone as it prepares to initiate the trial in the first half of 2026. The trial will assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders.

## FDA Clearance Already in Hand

Polaryx previously received a safe-to-proceed letter from the FDA in October 2025. The SOTERIA trial will incorporate natural history data as a control arm compared to the PLX-200 treated arm.

PLX-200 is an orally available compound derived from gemfibrozil. The company noted that compelling clinical activity could potentially lead to conditional marketing authorization.

## Stock Still Deep in Bearish Trend

Despite Tuesday’s surge, PLYX has declined 88.69% over the past 12 months and remains considerably closer to its 52-week low of $2.20 than its 52-week high of $48.91.

**PLYX Price Action:** Polaryx Therapeutics shares were down 22.47% at $3.07 at the time of publication on Wednesday, according to Benzinga Pro data.

_Photo by PeopleImages.com – Yuri A via Shutterstock_

### Related Stocks

- [PLYX.US](https://longbridge.com/en/quote/PLYX.US.md)

## Related News & Research

- [Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News](https://longbridge.com/en/news/282852650.md)
- [Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher   - Time to Buy?](https://longbridge.com/en/news/282762994.md)
- [NeuPath Health to Spotlight Chronic Pain Network at Bloom Burton Investor Conference](https://longbridge.com/en/news/282198112.md)
- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Danaher Unit Receives CE Mark for Rapid Infection Test](https://longbridge.com/en/news/282513203.md)